Skip to main content
    M

    Monte Rosa Therapeutics Inc (GLUE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.12
    +0.28 (+2.85%)

    Market Cap: $839.48M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    -68.01%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.22
    Range$-0.56 - $0.10
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.38+40.8%
    60d ago$-0.38+40.8%
    30d ago$-0.35+35.2%
    7d ago$-0.23+0.9%
    Current$-0.22
    Revenue Consensus
    $32M
    Range$0 - $67M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.46
    Range$-1.05 - $0.55
    8 analysts
    Revenue Consensus
    $12M
    Range$-42563140 - $135M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.46---
    Sep 26EST
    		-$-0.22---
    Jun 26
    Reported Aug 6
    		$-0.43$-0.25-72.00%Miss-186.7%
    Mar 26
    Reported May 7
    		$-0.45$-0.38-18.42%Miss-178.9%
    Dec 25
    Reported Mar 17
    		$-0.55$-0.33-67.58%Miss-53.6%
    Sep 25
    Reported Nov 6
    		$-0.33$-0.35+5.71%Beat-13.8%
    Jun 25
    Reported Aug 7
    		$-0.15N/A+51.61%Beat+65.1%
    Mar 25
    Reported May 8
    		$0.57$-0.32+278.13%Beat+207.5%
    Dec 24
    Reported Mar 20
    		$-0.36$0.18-298.94%Miss+38.3%
    Sep 24
    Reported Nov 7
    		$-0.29$-0.47+38.30%Beat+58.6%
    Jun 24
    Reported Aug 8
    		$-0.43$-0.54+20.37%Beat+39.4%
    Mar 24
    Reported May 9
    		$-0.53$-0.58+8.62%Beat+18.5%
    Dec 23
    Reported Mar 14
    		$-0.58$-0.33-75.76%Miss+7.9%
    Sep 23
    Reported Nov 9
    		$-0.70$-0.74+5.41%Beat-20.7%
    Jun 23
    Reported Aug 10
    		$-0.71$-0.69-2.90%Miss-24.6%
    Mar 23
    Reported May 11
    		$-0.65$-0.68+4.41%Beat-27.5%
    Dec 22
    Reported Mar 16
    		$-0.63$-0.62-1.61%Miss+32.3%
    Sep 22
    Reported Nov 10
    		$-0.58$-0.59+1.69%Beat-34.9%
    Jun 22
    Reported Aug 11
    		$-0.57$-0.47-21.28%Miss+84.3%
    Mar 22
    Reported May 11
    		$-0.51$-0.54+5.56%Beat+83.3%
    Dec 21
    Reported Mar 29
    		$-0.93$-0.50-86.00%Miss+87.1%
    Sep 21
    Reported Nov 10
    		$-0.43$-0.44+2.27%Beat+85.8%
    Jun 21
    Reported Aug 12
    		$-3.63$-0.38-855.26%Miss-
    Mar 21
    Reported Jun 25
    		$-3.06$-0.59-418.64%Miss-
    Dec 20
    Reported Mar 31
    		$-7.18$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-3.04$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-5.75EV/EBITDAN/A
    Price/FCF-32.01xFCF Yield-3.12%
    Profitability
    Profit Margin0.00%Operating Margin-548.00%
    ROE-42.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio10.58xQuick Ratio10.58x
    Trading Statistics
    Beta1.37Avg Volume1.49M
    52-Week High$25.7752-Week Low$8.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.18
    SMA 20$11.04
    SMA 50$13.13
    SMA 200$17.90
    EMA 10$10.38
    EMA 20$11.09
    EMA 50$13.24
    EMA 200$15.59

    MACD

    Line: -1.04Signal: -1.09Hist: 0.06

    ADX

    ADX: 40.4+DI: 12.8-DI: 28.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down76.0
    PSAR$10.61

    Bollinger Bands

    Upper Band$12.91
    Lower Band$9.17
    %B Position3383%(Upper)
    Band Width0.25

    RSI (14-Day)

    Neutral
    31.5

    Momentum Oscillators

    Stoch %K10.5
    Stoch %D14.6
    Williams %R-82.9
    ROC (10d)-10.1%
    Momentum-1.14
    CCI (20d)-77.9
    MFI (14d)36.8

    Volatility Measures

    ATR (14d)$0.66(6.5%)
    StdDev (20d)0.93
    Hist Vol50.9%(High)

    Volume Flow

    VWAP$10.08
    OBV38.9M
    AD Line11.9M
    CMF (20d)-0.178

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio1.0x
    VWMA (20d)$10.87

    Pivot Points

    R3$10.46
    R2$10.28
    R1$10.06
    Pivot Point$9.88
    S1$9.66
    S2$9.49
    S3$9.27

    Advanced Oscillators

    TSI-44.29
    Ultimate Osc44.0
    KST-238.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M$9.22M$4.70M$1.06M$8.75M$0
    Cost of Revenue$0$0$2.09M$0$0$0$2.06M$0$0$0$1.85M$0
    Gross Profit$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M$9.22M$4.70M$1.06M$-1,846,000$0
    Operating Expenses$58.10M$54.24M$52.50M$45.74M$38.75M$40.89M$47.64M$35.74M$37.34M$36.01M$34.86M$36.97M
    R&D$47.96M$44.07M$41.98M$36.68M$30.65M$32.19M$38.87M$27.62M$28.05M$27.03M$27.14M$28.31M
    SG&A$10.13M$10.18M$10.52M$9.06M$8.10M$8.70M$8.78M$8.13M$9.28M$8.98M$7.73M$8.66M
    Operating Income$-49,130,000$-50,034,000$-49,715,000$-32,975,000$-15,554,000$44.04M$13.00M$-26,527,000$-32,642,000$-34,947,000$-34,863,000$-36,968,000
    Interest Income$5.92M$5.59M$3.69M$2.75M$3.07M$3.44M$2.60M$2.89M$2.64M$2.44M$2.37M$2.23M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-43,189,000$-44,451,000$-46,076,000$-30,258,000$-11,096,000$47.71M$15.60M$-23,788,000$-30,058,000$-31,885,000$-33,274,000$-34,714,000
    Income Tax Expense$208,000$52,000$59,000$-3,177,000$1.20M$822,000$2.16M$71,000$252,000$83,000$-22,000$170,000
    Net Income$-43,397,000$-44,503,000$-46,135,000$-27,081,000$-12,295,000$46.88M$13.44M$-23,859,000$-30,310,000$-31,968,000$-33,252,000$-34,884,000
    EBITDA$-47,191,000$-48,013,000$-47,677,000$-30,909,000$-12,039,000$46.32M$15.07M$-24,577,000$-30,635,000$-32,430,000$-33,665,000$-35,107,000
    EBIT$-49,105,000$-50,042,000$-49,765,000$-33,004,000$-14,164,000$44.27M$13.01M$-26,680,000$-32,695,000$-34,327,000$-35,511,000$-36,941,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GLUE

    News

    UBS upgrades Monte Rosa Therapeutics stock to Hold while trials advance

    UBS has upgraded Monte Rosa Therapeutics (GLUE) stock to Hold after the company reported positive Phase 1 trial results for MRT-8102...

    ad-hoc-news.de•10/15/26•Neutral

    Monte Rosa Therapeutics (NASDAQ:GLUE) Raised to Hold at UBS Group

    UBS Group upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) to a "Hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $26.67. The company's shares opened at $9.89...

    MarketBeat•10/14/26•Neutral

    UBS raises target for Monte Rosa stock from USD 17 to USD 19

    UBS has increased its price target for Monte Rosa Therapeutics (GLUE) from $17.00 to $19.00, maintaining a Buy rating. This adjustment follows the company's Q2 2026 revenue of $8.97 million and a GAAP net loss of $43.40...

    ad-hoc-news.de•10/13/26•Bullish

    Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Rated "Moderate Buy" by Sell-Side Brokerages

    Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus rating from twelve analysts, with an average 12-month price target of $26.67...

    MarketBeat•10/13/26•Somewhat-Bearish

    UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating

    UBS has increased its price target for Monte Rosa Therapeutics (NASDAQ: GLUE) to $19 from $17, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook from the financial institution...

    Moomoo•10/13/26•Bullish

    GLUE Valuation and Fair Value

    P/E
    -5.8x
    Forward P/E
    10.0x
    P/FCF
    -32.0x
    P/B
    2.1x
    See GNG's fair value

    GLUE Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -548.0%
    Net margin
    0.0%
    ROE
    -42.7%
    FCF margin
    -111.7%
    FCF yield
    -3.1%

    GLUE Competitors

    CompanyTicker
    Cullinan Oncology LLCCGEM
    InMode LtdINMD
    Alto Neuroscience, Inc.ANRO
    P3 Health Partners IncPIII
    Jade Biosciences, Inc.JBIO
    Ardelyx IncARDX
    Si-Bone IncSIBN
    Esperion Therapeutics IncESPR

    Sector: Healthcare

    GLUE Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    2
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    GLUE Bull Case vs Bear Case

    Bull case

    • 100.0% of GLUE's analyst ratings are Buy or Strong Buy.

    Bear case

    • GLUE's quarterly revenue changed -61.3% year over year.

    GLUE Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -10.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.22
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About GLUE

    Does GLUE pay dividends?

    Monte Rosa Therapeutics Inc (GLUE) does not currently pay a regular dividend.

    What is GLUE's market cap?

    Monte Rosa Therapeutics Inc (GLUE) has a market capitalization of $839.48M with a current stock price of $10.12.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In